{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:07:59Z","timestamp":1792782479330,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSS Academy of Higher Education and Research, Mysore","id":[{"id":"https:\/\/ror.org\/013x70191","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05533-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:00:46Z","timestamp":1781236846000},"page":"18511-18530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies"],"prefix":"10.1007","volume":"399","author":[{"given":"Anisha","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Dharmashekara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargav","family":"Shreevatsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gonz\u00e1lez-Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogha","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Prasad","family":"Kollur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Shivamallu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. N. Nagendra","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"5533_CR1","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi Y, Ito K, Hayashi Y et al (2020) Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin Cancer Res 26:5962\u20135973","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5533_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/oncolo\/oyad106","volume":"28","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal C, Maity AP, Bauml JM et al (2023) A phase II open-label trial of binimetinib and hydroxychloroquine in patients with advanced KRAS-mutant NSCLC. Oncologist 28(7):644-e564","journal-title":"Oncologist"},{"issue":"6","key":"5533_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","volume":"11","author":"NS Akhave","year":"2021","unstructured":"Akhave NS, Biter AB, Hong DS (2021) Mechanisms of resistance to KRAS G12C-targeted therapy. Cancer Discov 11(6):1345\u20131352","journal-title":"Cancer Discov"},{"key":"5533_CR4","doi-asserted-by":"crossref","unstructured":"Andreani C, Bartolacci C, Melegari M et al (2025) Thioredoxin reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers. bioRxiv 2025.07.5.666783","DOI":"10.1101\/2025.07.25.666783"},{"issue":"11","key":"5533_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2553","volume":"5","author":"O Arrieta","year":"2019","unstructured":"Arrieta O, Barr\u00f3n F, Padilla M\u00c1S et al (2019) Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with EGFR-mutated lung adenocarcinoma: a phase 2 randomised clinical trial. JAMA Oncol 5(11):e192553","journal-title":"JAMA Oncol"},{"issue":"25","key":"5533_CR6","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II et al (2021) Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med 384(25):2382\u20132393","journal-title":"N Engl J Med"},{"key":"5533_CR7","doi-asserted-by":"crossref","unstructured":"Barlesi F, Felip E, Popat S et al (2024) CodeBreaK 202: sotorasib versus pembrolizumab plus platinum doublet chemotherapy as first-line treatment for PD-L1-negative KRAS G12C-mutated NSCLC (trial in progress). J Clin Oncol 42:TPS8653","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8653"},{"issue":"10503","key":"5533_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","volume":"406","author":"F Barlesi","year":"2025","unstructured":"Barlesi F, Yao W, Duruisseaux M et al (2025) Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet 406(10503):615\u2013626","journal-title":"Lancet"},{"issue":"1","key":"5533_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40164-023-00453-8","volume":"12","author":"F Batrash","year":"2023","unstructured":"Batrash F, Kutmah M, Zhang J (2023) The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC. Exp Hematol Oncol 12(1):93","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"5533_CR10","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"5533_CR11","first-page":"02936","volume":"S1556\u20130864","author":"TF Burns","year":"2025","unstructured":"Burns TF, Dragnev KH, Fujiwara Y et al (2025) Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor, in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC. J Thorac Oncol S1556\u20130864(25):02936\u201302943","journal-title":"J Thorac Oncol"},{"issue":"24","key":"5533_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413669","volume":"25","author":"J Costa","year":"2024","unstructured":"Costa J, Membrino A, Zanchetta C (2024) The role of ctDNA in the management of NSCLC in the AI and NGS era. Int J Mol Sci 25(24):13669","journal-title":"Int J Mol Sci"},{"issue":"10378","key":"5533_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J et al (2023) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial. Lancet 401(10378):733\u2013746","journal-title":"Lancet"},{"issue":"2","key":"5533_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1535-7163.MCT-25-0392","volume":"25","author":"S Deng","year":"2026","unstructured":"Deng S, Hussain T, Bartelli TF et al (2026) Repurposing of the macrolide antibiotic clarithromycin for the prevention of lung cancer. Mol Cancer Ther 25(2):283\u2013294","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"5533_CR15","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-14-0013","volume":"13","author":"JKT Dermawan","year":"2014","unstructured":"Dermawan JKT, Gurova K, Pink J et al (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-\u03baB, and cell-cycle progression in NSCLC. Mol Cancer Ther 13(9):2203\u20132214","journal-title":"Mol Cancer Ther"},{"issue":"6765","key":"5533_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1126\/science.adv7088","volume":"389","author":"S Dharmaiah","year":"2025","unstructured":"Dharmaiah S, Bonsor DA, Mo SP et al (2025) Structural basis for LZTR1 recognition of RAS GTPases for degradation. Science 389(6765):1112\u20131117","journal-title":"Science"},{"issue":"1","key":"5533_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/curroncol30010055","volume":"30","author":"G Doumat","year":"2023","unstructured":"Doumat G, Daher D, Zerdan MB et al (2023) Drug repurposing in non-small cell lung carcinoma: old solutions for new problems. Curr Oncol 30(1):704\u2013719","journal-title":"Curr Oncol"},{"issue":"suppl 16","key":"5533_CR18","doi-asserted-by":"publisher","first-page":"8519","DOI":"10.1200\/JCO.2025.43.16_suppl.8519","volume":"43","author":"K Dragnev","year":"2025","unstructured":"Dragnev K, Murciano-Goroff Y, Ammakkanavar N et al (2025) Safety and efficacy of olomorasib + immunotherapy in first-line KRAS G12C-mutant advanced NSCLC: update from LOXO-RAS-20001. J Clin Oncol 43(suppl 16):8519","journal-title":"J Clin Oncol"},{"key":"5533_CR19","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy GK, Govindan R, Velcheti V et al (2023) Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated NSCLC: 2-year analysis of CodeBreaK 100. J Clin Oncol 41:3311\u20133317","journal-title":"J Clin Oncol"},{"issue":"7","key":"5533_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1158\/2159-8290.CD-25-0349","volume":"15","author":"RY Ebright","year":"2025","unstructured":"Ebright RY, Dilly J, Shaw AT et al (2025) Response and resistance to RAS inhibition in cancer. Cancer Discov 15(7):132\u20131349","journal-title":"Cancer Discov"},{"key":"5533_CR21","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","volume":"14","author":"B El Osta","year":"2019","unstructured":"El Osta B, Behera M, Kim S et al (2019) Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience. J Thorac Oncol 14:876\u2013889","journal-title":"J Thorac Oncol"},{"key":"5533_CR22","unstructured":"Eli Lilly and Company (n.d.) Lilly\u2019s olomorasib receives U.S. FDA breakthrough therapy designation for first-line metastatic KRAS G12C-mutant lung cancers. Press release, September 4, 2025. https:\/\/investor.lilly.com.\u00a0Accessed 03 Feb 2026"},{"key":"5533_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105074","volume":"102","author":"SM Ernst","year":"2024","unstructured":"Ernst SM, Hofman MM, van der Horst TE et al (2024) Hepatotoxicity in patients with NSCLC treated with sotorasib after prior immunotherapy. EBioMedicine 102:105074","journal-title":"EBioMedicine"},{"key":"5533_CR24","doi-asserted-by":"crossref","unstructured":"Falchook G, Li BT, Marrone KA et al (2022) Sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors. J Thorac Oncol 17:S8","DOI":"10.1016\/j.jtho.2022.07.022"},{"key":"5533_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","volume":"124","author":"I Ferrer","year":"2018","unstructured":"Ferrer I, Zugazagoitia J, Herbertz S et al (2018) KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer 124:53\u201364","journal-title":"Lung Cancer"},{"issue":"1","key":"5533_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104250","volume":"30","author":"P Filis","year":"2025","unstructured":"Filis P, Salgkamis D, Matikas A et al (2025) Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236. Drug Discov Today 30(1):104250","journal-title":"Drug Discov Today"},{"issue":"3","key":"5533_CR27","first-page":"S8","volume":"20","author":"MC Garassino","year":"2025","unstructured":"Garassino MC, Theelen WSME, J\u00e4nne PA et al (2025) First-line adagrasib with pembrolizumab in patients with KRAS G12C-mutated NSCLC and PD-L1 \u2265 50% from phase II of KRYSTAL-7. J Clin Oncol 20(3):S8\u2013S10","journal-title":"J Clin Oncol"},{"issue":"3","key":"5533_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.lungcan.2015.10.008","volume":"90","author":"DE Gerber","year":"2015","unstructured":"Gerber DE, Boothman DA, Fattah FJ et al (2015) Phase 1 study of romidepsin plus erlotinib in advanced NSCLC. Lung Cancer 90(3):534\u2013541","journal-title":"Lung Cancer"},{"issue":"8","key":"5533_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/17460441.2021.1912733","volume":"16","author":"C Gil","year":"2021","unstructured":"Gil C, Martinez A (2021)\u00a0Is drug repurposing really the future of drug discovery or is new innovation truly the way forward? Expert Opin Drug Discov 16(8):829\u2013831","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"5533_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101913","volume":"6","author":"L Gui","year":"2025","unstructured":"Gui L, Chen K, Yan J, Chen P, Gao WQ, Ma B (2025) Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity. Cell Rep Med 6(2):101913","journal-title":"Cell Rep Med"},{"key":"5533_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41586-025-08931-1","volume":"642","author":"ZJ Hauseman","year":"2025","unstructured":"Hauseman ZJ, Stauffer F, Beyer KS et al (2025) Targeting the SHOC2\u2013RAS interaction in RAS-mutant cancers. Nature 642:232\u2013241","journal-title":"Nature"},{"key":"5533_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.annonc.2023.10.790","volume":"35","author":"MJ Hochmair","year":"2024","unstructured":"Hochmair MJ et al (2024) Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC. Ann Oncol 35:142\u2013144","journal-title":"Ann Oncol"},{"key":"5533_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.822865","volume":"11","author":"AS Jain","year":"2021","unstructured":"Jain AS, Prasad A, Pradeep S et al (2021) Corrigendum: everything old is new again: drug repurposing approach for non-small cell lung cancer targeting MAPK signaling pathway. Front Oncol 11:822865","journal-title":"Front Oncol"},{"issue":"2","key":"5533_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM et al (2022) Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation. N Engl J Med 387(2):120\u2013131","journal-title":"N Engl J Med"},{"key":"5533_CR35","doi-asserted-by":"publisher","first-page":"8500","DOI":"10.1200\/JCO.2025.43.16_suppl.8500","volume":"43","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Theelen WSME, Garassino MC et al (2025) First-line adagrasib with pembrolizumab in patients with advanced\/metastatic KRAS G12C-mutated NSCLC from the phase 2 portion of the KRYSTAL-7 study. J Clin Oncol 43:8500","journal-title":"J Clin Oncol"},{"key":"5533_CR36","doi-asserted-by":"crossref","unstructured":"Keating AT, Papadopoulos KP, Hloros E et al (2024) Phase 1\/2 study of FMC-376, an oral KRAS G12C dual inhibitor (PROSPER). J Clin Oncol 42:TPS3184","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3184"},{"issue":"2","key":"5533_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.21873\/invivo.11498","volume":"33","author":"C Kitagawa","year":"2019","unstructured":"Kitagawa C, Mori M, Ichiki M et al (2019) Gefitinib plus bevacizumab vs. gefitinib alone for EGFR mutant non-squamous NSCLC. In Vivo 33(2):477\u201382","journal-title":"In Vivo"},{"issue":"12","key":"5533_CR38","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/2159-8290.CD-23-1529","volume":"14","author":"O Klingbeil","year":"2024","unstructured":"Klingbeil O, Skopelitis D, Tonelli C et al (2024) MARK2\/MARK3 kinases are catalytic codependencies of YAP\/TAZ in human cancer. Cancer Discov 14(12):2471\u20132488","journal-title":"Cancer Discov"},{"key":"5533_CR39","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T et al (2021) KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors and overcoming strategies. J Thorac Oncol 16:1321\u20131332","journal-title":"J Thorac Oncol"},{"issue":"12","key":"5533_CR40","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.21037\/tlcr-24-603","volume":"13","author":"E Lee","year":"2024","unstructured":"Lee E, Lee SY, Seong YJ et al (2024) Lung cancer organoid-based drug evaluation models and new drug development application trends. Transl Lung Cancer Res 13(12):3741\u20133763","journal-title":"Transl Lung Cancer Res"},{"issue":"suppl 16","key":"5533_CR41","first-page":"8511","volume":"42","author":"BT Li","year":"2024","unstructured":"Li BT, Clarke JM, Falchook GS et al (2024) CodeBreaK 101: updated analysis of sotorasib with carboplatin and pemetrexed as first-line therapy in KRAS G12C advanced NSCLC. J Clin Oncol 42(suppl 16):8511","journal-title":"J Clin Oncol"},{"key":"5533_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","volume":"12","author":"Z Li","year":"2024","unstructured":"Li Z, Song Z, Zhao Y et al (2024) D-1553 (Garsorasib), a potent and selective inhibitor of KRASG12C in patients with NSCLC. Lancet Respir Med 12:589\u2013598","journal-title":"Lancet Respir Med"},{"key":"5533_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/EDBK_351333","volume":"42","author":"CD Lietman","year":"2022","unstructured":"Lietman CD, Johnson ML, McCormick F et al (2022) More to the RAS story: KRAS G12C inhibition, resistance mechanisms, and moving beyond KRAS G12C. Am Soc Clin Oncol Educ Book 42:205\u2013217","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"5533_CR44","doi-asserted-by":"crossref","unstructured":"Liu Z, Liu Y, Qian L et al (2021) A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell 81(19):4076\u20134090.e8.4;14(6):982\u2013993","DOI":"10.1016\/j.molcel.2021.07.021"},{"key":"5533_CR45","first-page":"161","volume":"15","author":"FX Luo","year":"2024","unstructured":"Luo FX, Arter ZL (2024) Adagrasib in KRYSTAL-12 has broken the KRAS G12C enigma code in NSCLC. Lung Cancer 15:161\u2013167","journal-title":"Lung Cancer"},{"issue":"6662","key":"5533_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv X, Lu X, Cao J et al (2023) Modulation of the proteostasis network promotes tumour resistance to oncogenic KRAS inhibitors. Science 381(6662):eabn4180","journal-title":"Science"},{"issue":"3","key":"5533_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","volume":"15","author":"AE Maciag","year":"2025","unstructured":"Maciag AE, Stice JP, Wang B et al (2025) Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C. Cancer Discov 15(3):578\u2013594","journal-title":"Cancer Discov"},{"key":"5533_CR48","volume":"21","author":"J Malhotra","year":"2019","unstructured":"Malhotra J, Jabbour S, Orlick M et al (2019) Phase Ib\/II study of hydroxychloroquine plus chemotherapy in metastatic NSCLC. Cancer Treat Res Commun 21:100158","journal-title":"Cancer Treat Res Commun"},{"issue":"814","key":"5533_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adt5511","volume":"17","author":"KM McAndrews","year":"2025","unstructured":"McAndrews KM, Paradiso F, Stalnecker CA et al (2025) An allele-agnostic mutant-KRAS inhibitor suppresses tumour maintenance signals and reprograms tumour immunity in pancreatic cancer. Sci Transl Med 17(814):eadt5511","journal-title":"Sci Transl Med"},{"key":"5533_CR50","doi-asserted-by":"crossref","unstructured":"Meraz IM, Wu S, Xu Y et al (2025) Acquired resistance to sotorasib in KRAS G12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1 regulator of cap-dependent translation. bioRxiv 18:643954","DOI":"10.7554\/eLife.106875.1"},{"key":"5533_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1380584","volume":"14","author":"H Miyashita","year":"2024","unstructured":"Miyashita H, Kato S, Hong DS (2024) KRAS G12C inhibitor combination therapies: current evidence and challenge. Front Oncol 14:1380584","journal-title":"Front Oncol"},{"issue":"3","key":"5533_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12032-021-01475-0","volume":"38","author":"AW Mohamed","year":"2021","unstructured":"Mohamed AW, Elbassiouny M, Elkhodary DA et al (2021) The effect of itraconazole on outcomes of patients with advanced NSCLC receiving platinum-based chemotherapy. Med Oncol 38(3):23","journal-title":"Med Oncol"},{"issue":"41","key":"5533_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade3816","volume":"9","author":"A Mohanty","year":"2023","unstructured":"Mohanty A, Nam A, Srivastava S et al (2023) Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer. Sci Adv 9(41):eade3816","journal-title":"Sci Adv"},{"issue":"3","key":"5533_CR54","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","volume":"42","author":"M Molina-Arcas","year":"2024","unstructured":"Molina-Arcas M, Downward J (2024) Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell 42(3):338\u2013357","journal-title":"Cancer Cell"},{"issue":"4","key":"5533_CR55","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2014-0424","volume":"20","author":"H Nechushtan","year":"2015","unstructured":"Nechushtan H, Hamamreh Y, Nidal S et al (2015) A phase IIb trial of disulfiram added to chemotherapy for metastatic NSCLC. Oncologist 20(4):366\u2013367","journal-title":"Oncologist"},{"key":"5533_CR56","doi-asserted-by":"crossref","unstructured":"Negrao MV, Arbour KC, Burns TF et al (2024) SUNRAY-01, a pivotal global study of olomorasib plus pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC. J Clin Oncol 42:TPS8649","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8649"},{"issue":"12_Supplement","key":"5533_CR57","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-3595","volume":"82","author":"RJ Nichols","year":"2022","unstructured":"Nichols RJ et al (2022) Abstract 3595: RMC-6291, a next-generation tri-complex KRAS G12C(ON) inhibitor, outperforms KRAS G12C(OFF) inhibitors in preclinical models of KRAS G12C cancers. Cancer Res 82(12_Supplement):3595","journal-title":"Cancer Res"},{"issue":"1","key":"5533_CR58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41420-026-02998-z","volume":"12","author":"D Olmo-Gonz\u00e1lez","year":"2026","unstructured":"Olmo-Gonz\u00e1lez D, Zhou M, Oliveira NG et al (2026) Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells. Cell Death Discov 12(1):134","journal-title":"Cell Death Discov"},{"key":"5533_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107886","volume":"194","author":"Y Oya","year":"2024","unstructured":"Oya Y, Imaizumi K, Mitsudomi T (2024) The next-generation KRAS inhibitors\u2026what comes after sotorasib and adagrasib? Lung Cancer 194:107886","journal-title":"Lung Cancer"},{"issue":"24","key":"5533_CR60","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1158\/0008-5472.CAN-23-1127","volume":"83","author":"A Prahallad","year":"2023","unstructured":"Prahallad A, Weiss A, Voshol H et al (2023) CRISPR screening identifies mechanisms of resistance to KRAS G12C and SHP2 inhibitor combinations in NSCLC. Cancer Res 83(24):4130\u20134141","journal-title":"Cancer Res"},{"issue":"1","key":"5533_CR61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5306\/wjco.v10.i1.14","volume":"10","author":"KM Prezzano","year":"2019","unstructured":"Prezzano KM, Ma SJ, Hermann GM et al (2019) Stereotactic body radiation therapy for non-small cell lung cancer: a review. World J Clin Oncol 10(1):14\u201327","journal-title":"World J Clin Oncol"},{"issue":"10","key":"5533_CR62","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jamaoncol.2019.2095","volume":"5","author":"R Rengan","year":"2019","unstructured":"Rengan R, Mick R, Pryma DA et al (2019) Clinical outcomes of nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA\/IIIB NSCLC: a phase 1\/2 trial. JAMA Oncol 5(10):1464\u20131472","journal-title":"JAMA Oncol"},{"issue":"6","key":"5533_CR63","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","volume":"36","author":"JM Riedl","year":"2025","unstructured":"Riedl JM, Fece de la Cruz F, Lin JJ et al (2025) Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS G12C inhibitors. Ann Oncol 36(6):682\u2013692","journal-title":"Ann Oncol"},{"key":"5533_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104228","volume":"195","author":"R Rosell","year":"2024","unstructured":"Rosell R, Codony-Servat J, Gonz\u00e1lez J et al (2024) KRAS G12C-mutant driven non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol 195:104228","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"5533_CR65","first-page":"500","volume":"20","author":"R Rosell","year":"2023","unstructured":"Rosell R, Jain A, Codony-Servat J et al (2023) Biological insights in non-small cell lung cancer. Cancer Biol Med 20(7):500\u2013518","journal-title":"Cancer Biol Med"},{"issue":"1","key":"5533_CR66","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12964-024-01667-x","volume":"22","author":"R Rosell","year":"2024","unstructured":"Rosell R, Jantus-Lewintre E, Cao P et al (2024) KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination. Cell Commun Signal 22(1):324","journal-title":"Cell Commun Signal"},{"key":"5533_CR67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41392-025-02274-z","volume":"10","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Wu HX, Xu Y et al (2025) Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, in colorectal cancer: phase II trial. Signal Transduct Target Ther 10:189","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"5533_CR68","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JTO.0b013e31828c3950","volume":"8","author":"CM Rudin","year":"2013","unstructured":"Rudin CM, Brahmer JR, Juergens RA et al (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous NSCLC. J Thorac Oncol 8(5):619\u2013623","journal-title":"J Thorac Oncol"},{"issue":"8","key":"5533_CR69","doi-asserted-by":"publisher","first-page":"10574","DOI":"10.1096\/fj.202000052R","volume":"34","author":"CF Ruiz","year":"2020","unstructured":"Ruiz CF, Montal ED, Haley JA, Bott AJ, Haley JD (2020) SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC. FASEB J 34(8):10574\u201310589","journal-title":"FASEB J"},{"issue":"8","key":"5533_CR70","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher A, LoRusso P, Patel MR et al (2023) Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med 389(8):710\u2013721","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"5533_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35783","volume":"131","author":"K Shaverdashvili","year":"2025","unstructured":"Shaverdashvili K, Burns TF (2025) Advances in the treatment of KRAS G12C mutant non-small cell lung cancer. Cancer 131(Suppl 1):e35783","journal-title":"Cancer"},{"issue":"25","key":"5533_CR72","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK et al (2021) Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 384(25):2371\u20132381","journal-title":"N Engl J Med"},{"key":"5533_CR73","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","volume":"31","author":"F Skoulidis","year":"2025","unstructured":"Skoulidis F, Li BT, de Langen AJ et al (2025) Molecular determinants of sotorasib clinical efficacy in KRAS G12C-mutated non-small-cell lung cancer. Nat Med 31:2755\u20132767","journal-title":"Nat Med"},{"issue":"6758","key":"5533_CR74","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.adq2004","volume":"389","author":"DK Simanshu","year":"2025","unstructured":"Simanshu DK, Xu R, Stice JP et al (2025) BBO-10203 inhibits tumour growth without inducing hyperglycaemia by blocking RAS\u2013PI3K\u03b1 interaction. Science 389(6758):409\u2013415","journal-title":"Science"},{"key":"5533_CR75","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/JCO.24.00310","volume":"43","author":"H Singh","year":"2025","unstructured":"Singh H, Vellanki PJ, Pazdur R (2025) The retrofit: lessons from sotorasib\u2019s dosing conundrum. J Clin Oncol 43:248\u2013250","journal-title":"J Clin Oncol"},{"issue":"8","key":"5533_CR76","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jtho.2021.02.004","volume":"16","author":"N Singh","year":"2021","unstructured":"Singh N, Agrawal S (2021) Lung cancer in India. J Thorac Oncol 16(8):1250\u20131266","journal-title":"J Thorac Oncol"},{"issue":"9","key":"5533_CR77","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1158\/1078-0432.CCR-20-4128","volume":"27","author":"M Skwarski","year":"2021","unstructured":"Skwarski M, McGowan DR, Belcher E et al (2021) Mitochondrial inhibitor atovaquone increases tumour oxygenation and inhibits hypoxic gene expression in NSCLC. Clin Cancer Res 27(9):2459\u20132469","journal-title":"Clin Cancer Res"},{"issue":"11","key":"5533_CR78","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","volume":"19","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, Goldman J, El-Hariry I et al (2013) A multicenter phase II study of ganetespib monotherapy in advanced NSCLC. Clin Cancer Res 19(11):3068\u20133077","journal-title":"Clin Cancer Res"},{"issue":"50","key":"5533_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq4274","volume":"10","author":"X Song","year":"2024","unstructured":"Song X, Zhou Z, Elmezayen A et al (2024) SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Sci Adv 10(50):eadq4274","journal-title":"Sci Adv"},{"issue":"3","key":"5533_CR80","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"5533_CR81","doi-asserted-by":"publisher","first-page":"12046","DOI":"10.3390\/ijms241512046","volume":"24","author":"O Urz\u00ec","year":"2023","unstructured":"Urz\u00ec O, Gasparro R, Costanzo E et al (2023) Three-dimensional cell cultures: the bridge between In vitro and in vivo models. Int J Mol Sci 24(15):12046","journal-title":"Int J Mol Sci"},{"issue":"10","key":"5533_CR82","doi-asserted-by":"publisher","first-page":"S976","DOI":"10.1016\/j.jtho.2019.08.2141","volume":"14","author":"P Viveiros","year":"2019","unstructured":"Viveiros P, Burns M, Davis A et al (2019) Response to combination of metformin and nivolumab in a NSCLC patient whose disease progressed on nivolumab. J Thorac Oncol 14(10):S976","journal-title":"J Thorac Oncol"},{"issue":"4","key":"5533_CR83","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1158\/1078-0432.CCR-24-1722","volume":"31","author":"MS von Itzstein","year":"2025","unstructured":"von Itzstein MS, Burns TF, Dowell JE et al (2025) Phase I\/II trial of exportin 1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS-mutant non-small cell lung cancer. Clin Cancer Res 31(4):639\u2013648","journal-title":"Clin Cancer Res"},{"key":"5533_CR84","doi-asserted-by":"crossref","unstructured":"Waizenegger IC, Lu H, Thamer C et al (2022) Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor, as monotherapy and in combination with BI 1701963. Cancer Res 82(12_Supplement):2667","DOI":"10.1158\/1538-7445.AM2022-2667"},{"issue":"15","key":"5533_CR85","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/0008-5472.CAN-24-3525","volume":"85","author":"K Wang","year":"2025","unstructured":"Wang K, Li J, Zhang H et al (2025) Tobacco smoking rewires cell metabolism by inducing GAPDH succinylation to promote lung cancer progression. Cancer Res 85(15):2838\u20132857","journal-title":"Cancer Res"},{"issue":"6","key":"5533_CR86","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/aps.2016.39","volume":"37","author":"LJ Wang","year":"2016","unstructured":"Wang LJ, Li J, Hao FR et al (2016) Dexamethasone suppresses the growth of human NSCLC via inducing estrogen sulfotransferase and inactivating estrogen. Acta Pharmacol Sin 37(6):845\u2013856","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"5533_CR87","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2767-9764.CRC-25-0001","volume":"5","author":"P Wang","year":"2025","unstructured":"Wang P, Sun X, He X et al (2025) Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism with cetuximab or SHP2 inhibitor JAB-3312. Cancer Res Commun 5(5):792\u2013803","journal-title":"Cancer Res Commun"},{"issue":"1","key":"5533_CR88","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijrobp.2019.10.010","volume":"106","author":"XS Wang","year":"2020","unstructured":"Wang XS, Shi Q, Mendoza T et al (2020) Minocycline reduces chemoradiation-related symptom burden in NSCLC: a phase 2 randomised trial. Int J Radiat Oncol Biol Phys 106(1):100\u2013107","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5533_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107921","volume":"196","author":"DM Waterhouse","year":"2024","unstructured":"Waterhouse DM et al (2024) Patient-reported outcomes in CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C NSCLC. Lung Cancer 196:107921","journal-title":"Lung Cancer"},{"issue":"25","key":"5533_CR90","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1016\/j.cell.2024.09.032","volume":"187","author":"L Xu","year":"2024","unstructured":"Xu L, Peng F, Luo Q et al (2024) IRE1\u03b1 silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell 187(25):7248-7266.e34","journal-title":"Cell"},{"issue":"6","key":"5533_CR91","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger R, Uboha NV, Pelster MS et al (2024) Efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated metastatic colorectal cancer. Cancer Discov 14(6):982\u2013993","journal-title":"Cancer Discov"},{"issue":"11","key":"5533_CR92","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1111\/1759-7714.13675","volume":"11","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Yano Y, Kuge T et al (2020) Pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and NSCLC. Thorac Cancer 11(11):3317\u20133325","journal-title":"Thorac Cancer"},{"issue":"24","key":"5533_CR93","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.178535","volume":"9","author":"W Yang","year":"2024","unstructured":"Yang W, Zhang M, Zhang TX et al (2024) YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis. JCI Insight 9(24):e178535","journal-title":"JCI Insight"},{"key":"5533_CR94","doi-asserted-by":"publisher","first-page":"8616","DOI":"10.1200\/JCO.2024.42.16_suppl.8616","volume":"42","author":"H Yoshioka","year":"2024","unstructured":"Yoshioka H, Akamatsu H, Sakata S et al (2024) Final analysis of SCARLET study: sotorasib plus carboplatin-pemetrexed in KRAS G12C non-squamous NSCLC. J Clin Oncol 42:8616","journal-title":"J Clin Oncol"},{"issue":"34","key":"5533_CR95","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2512404122","volume":"122","author":"E Zamorano-Dominguez","year":"2025","unstructured":"Zamorano-Dominguez E, Morales-Cacho L, Barrero R et al (2025) Systemic Kras ablation disrupts myeloid cell homeostasis in adult mice. Proc Natl Acad Sci USA 122(34):e2512404122","journal-title":"Proc Natl Acad Sci USA"},{"key":"5533_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100250","volume":"8","author":"B Zhang","year":"2021","unstructured":"Zhang B, Zhang Y, Zhang J et al (2021) Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP signaling. Adv Sci 8:2100250","journal-title":"Adv Sci"},{"issue":"9","key":"5533_CR97","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1158\/2159-8290.CD-24-0006","volume":"14","author":"J Zhang","year":"2024","unstructured":"Zhang J, Lim SM, Yu MR et al (2024) D3S\u2013001, a KRAS G12C inhibitor with rapid target engagement kinetics, overcomes nucleotide cycling. Cancer Discov 14(9):1675\u20131698","journal-title":"Cancer Discov"},{"issue":"834","key":"5533_CR98","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adx6873","volume":"18","author":"Y Zhong","year":"2026","unstructured":"Zhong Y, Geng F, Su H et al (2026) SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibition. Sci Transl Med 18(834):eadx6873","journal-title":"Sci Transl Med"},{"key":"5533_CR99","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","volume":"19","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng X, Sun L et al (2024) Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study. J Thorac Oncol 19:1630\u20131639","journal-title":"J Thorac Oncol"},{"issue":"1","key":"5533_CR100","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu C, Guan X, Zhang X et al (2022) Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer 21(1):159","journal-title":"Mol Cancer"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05533-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:02:57Z","timestamp":1791540177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05533-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5533"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05533-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI and AI-assisted technologies were not used in the preparation of this work.","order":4,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}